Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes
Fuente:
Redalyc
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artículo científico |
| Sprache: | en |
| Veröffentlicht: |
Sociedad Latinoamericana de Hipertensión
2007
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1876484517303156736 |
|---|---|
| author | Valmore Bermúdez |
| author_facet | Valmore Bermúdez |
| contents | Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes Valmore Bermúdez Raquel Cano Clímaco Cano Fernando Bermúdez Elliuz Leal Karen Acosta Edgardo Mengual Nailet Arraiz Carlos Briceño Juan Gómez Magaly Bustamante Daniel Aparicio Mayela Cabrera Lysney Valdelamar Moisés Rodríguez Manuel Velasco Zafar Israili Rafael Hernández Medicina HOMA insulin type 2 diabetes Objectives Type 2 diabetes mellitus is a metabolic disorder that results from defects in both insulin secretion and insulin action. Questions remain about when insulin therapy must be indicated, thus the aim of this study was to evaluate HOMA'cell as surrogate criteria for insulin therapy indication in patients with type 2 diabetes. Subjects And Methods A prospective study was performed in 189 type 2 diabetic patients with deficient metabolic control assessed by clinical and laboratory parameters. All patients received nutritional intervention and combination therapy with Metformin and Glimepiride. Patients that did not respond were admitted to the next phase, which consisted in Glimepiride+Metformin+Rosiglitazone oral therapy and then, revaluated after 3 months. Comparisons between responders and non-responders in this phase were made in order to achieve differences in metabolic parameters and ¿cell function. Results Out of 189 patients studied, 150 (79,36%) were considered as fully responders in the first phase of this study. The remaining 39 patients were admitted in the second trial phase in which 20 patients (51,28%) responded to triple oral therapy, while the other 19 (49,72%) required insulin therapy. Significant differences were found in fasting and post-pandrial glycemia (p<0,001; p<0,004) between the non-insulin requiring group (200±12,0 mg/dl; 266,05±17,67 mg/dl) and the insulin-requiring group (291,5±17,6 mg/dl; 361,6±26,1 mg/dl). Likewise, significant differences were observed in HOMAIR and HOMA'cell (p<0,002; p<0,04) between non-insulin requiring patients (7,7±0,8; 24,5±1,3%) vs. insulin-requiring patients (12,6±1,2; 19,4±2,4%). Finally, significant differences were observed when comparing body mass index (non-insulin requiring group 29,2±0,4 Kg/mt2 vs. insulin-requiring group 27,1±0,9 Kg/mt2; p<0,05). Conclusions HOMA'cell determination in the clinical practice is a useful tool to assess when insulin therapy should be started type 2 diabetic patients. 2007 artículo científico 1856-4550 https://www.redalyc.org/articulo.oa?id=170216979005 en http://www.redalyc.org/revista.oa?id=1702 Revista Latinoamericana de Hipertensión application/pdf Sociedad Latinoamericana de Hipertensión Revista Latinoamericana de Hipertensión (República Bolivariana de Venezuela) Num.4 Vol.2 |
| format | Artículo científico |
| id | redalyc_170216979005 |
| institution | Redalyc |
| language | en |
| publishDate | 2007 |
| publisher | Sociedad Latinoamericana de Hipertensión |
| spellingShingle | Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes Valmore Bermúdez Medicina HOMA insulin type 2 diabetes Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes Valmore Bermúdez Raquel Cano Clímaco Cano Fernando Bermúdez Elliuz Leal Karen Acosta Edgardo Mengual Nailet Arraiz Carlos Briceño Juan Gómez Magaly Bustamante Daniel Aparicio Mayela Cabrera Lysney Valdelamar Moisés Rodríguez Manuel Velasco Zafar Israili Rafael Hernández Medicina HOMA insulin type 2 diabetes Objectives Type 2 diabetes mellitus is a metabolic disorder that results from defects in both insulin secretion and insulin action. Questions remain about when insulin therapy must be indicated, thus the aim of this study was to evaluate HOMA'cell as surrogate criteria for insulin therapy indication in patients with type 2 diabetes. Subjects And Methods A prospective study was performed in 189 type 2 diabetic patients with deficient metabolic control assessed by clinical and laboratory parameters. All patients received nutritional intervention and combination therapy with Metformin and Glimepiride. Patients that did not respond were admitted to the next phase, which consisted in Glimepiride+Metformin+Rosiglitazone oral therapy and then, revaluated after 3 months. Comparisons between responders and non-responders in this phase were made in order to achieve differences in metabolic parameters and ¿cell function. Results Out of 189 patients studied, 150 (79,36%) were considered as fully responders in the first phase of this study. The remaining 39 patients were admitted in the second trial phase in which 20 patients (51,28%) responded to triple oral therapy, while the other 19 (49,72%) required insulin therapy. Significant differences were found in fasting and post-pandrial glycemia (p<0,001; p<0,004) between the non-insulin requiring group (200±12,0 mg/dl; 266,05±17,67 mg/dl) and the insulin-requiring group (291,5±17,6 mg/dl; 361,6±26,1 mg/dl). Likewise, significant differences were observed in HOMAIR and HOMA'cell (p<0,002; p<0,04) between non-insulin requiring patients (7,7±0,8; 24,5±1,3%) vs. insulin-requiring patients (12,6±1,2; 19,4±2,4%). Finally, significant differences were observed when comparing body mass index (non-insulin requiring group 29,2±0,4 Kg/mt2 vs. insulin-requiring group 27,1±0,9 Kg/mt2; p<0,05). Conclusions HOMA'cell determination in the clinical practice is a useful tool to assess when insulin therapy should be started type 2 diabetic patients. 2007 artículo científico 1856-4550 https://www.redalyc.org/articulo.oa?id=170216979005 en http://www.redalyc.org/revista.oa?id=1702 Revista Latinoamericana de Hipertensión application/pdf Sociedad Latinoamericana de Hipertensión Revista Latinoamericana de Hipertensión (República Bolivariana de Venezuela) Num.4 Vol.2 |
| title | Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes |
| topic | Medicina HOMA insulin type 2 diabetes |
| url | https://www.redalyc.org/articulo.oa?id=170216979005 |